BeOne Medicines (ONC) Q3 2026 Earnings Call Transcript

BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% year over year, with GAAP operating income rising 157% to $419 million and free cash flow increasing 34% to $474 million. The company raised full-year revenue guidance to $6.9 billion–$7.0 billion from $6.6 billion–$6.8 billion and GAAP operating income guidance by $200 million to $1.2 billion–$1.3 billion. BRUKINSA sales grew 34% to $1.41 billion, including U.S. sales above $1 billion; management also reported encouraging early oncology pipeline response data. Risks include expected revenue pressure for certain Amgen-licensed brands beyond 2026, a potential modest 2027 headwind from Medicare Part D liability, and an FDA-requested follow-up that shifts the potential tacabrutideg filing to mid-2027.

Analysis

BeOne (6160) offers a rare biotech setup where the commercial engine can fund a widening late-stage pipeline, but the near-term earnings slope may be less powerful than the revenue growth suggests. Normalize BRUKINSA for the disclosed shipment/timing benefit and China growth for FX; neither changes demand direction, but both make the quarter a weak run-rate anchor. The 2027 Medicare Part D liability shift and continued R&D spending also argue against extrapolating 2026 margin expansion. A prospective Q4 tax-allowance reversal is a one-time reported-earnings uplift, not recurring cash earnings.

The main valuation optionality is solid tumors, not the already-scaled BRUKINSA franchise. The response rates for the GPC3 bispecific, PRMT5 inhibitor, and CEA ADC are early, selected-cohort signals; small samples, follow-up, and confirmatory trial execution remain decisive. The GPC3 first-line phase III start and upcoming ASH data are nearer catalysts, while meaningful revenue contribution is a multi-year, 6–18 month-plus question. A larger CDK4 trial may improve statistical power, but does not itself de-risk efficacy. Conversely, a mid-2027 tacabrutideg filing plan leaves regulatory and durability risk; the head-to-head study matters more to long-run positioning than accelerated approval.

Amgen in-licensed portfolio pressure is a contained BeOne portfolio risk; do not infer a material AMGN earnings impact without contract economics. RVMD gains a development partner and combination path, but BeOne’s trial execution is not proof of clinical synergy. Contrarian: the market may capitalize several unvalidated solid-tumor programs before pivotal evidence; strong operating execution alone does not justify paying for all pipeline optionality.

Key Decisions for Investors

• Prefer a staged long in 6160 over a chase after the results: add on post-event weakness only if underlying BRUKINSA demand and full-year guidance remain intact. Reassess if guidance is cut, or if subsequent reports show sustained deterioration in U.S. new-patient starts or treatment duration.
• Treat ASH and 2027 pivotal-trial updates as defined catalyst windows, not as validated commercial assets. Keep exposure sized to tolerate negative or inconclusive data; monitor response durability, safety, enrollment, and regulatory feedback.
• Do not use Q4 GAAP net income as a recurring-earnings proxy. Separate the valuation-allowance benefit from operating performance, and track 2027 operating expense growth and Medicare Part D costs against revenue growth.
• For AMGN, monitor BeOne’s XGEVA/KYPROLIS biosimilar and potential VBP exposure as a diligence item, not a standalone short thesis: the transcript does not establish the relevant royalty or profit-share contribution to Amgen.